ClinicalTrials.gg
CompletedNCT05253807FIGHT-210Updated Aug 5, 2025Results posted

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

A Phase 2 interventional study of Pemigatinib in Non-Small Cell Lung Cancer (NSCLC), sponsored by Incyte Corporation. Completed at 36 sites in 5 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-08-05.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Carcinoma, Non-Small-Cell Lung by Incyte Corporation — 1 open to participants now, 1 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Incyte Corporation.

Enrollment
24th of 30
8 · median 53
Started
2022
the only one that year
Phase 2
9 of 30
none open now
Registered
27th of 30
by date

Among the 30 studies in Carcinoma, Non-Small-Cell Lung by Incyte Corporation, this one is the 24th largest by enrollment, is the only one that started in 2022, is one of 9 in phase 2, and was the 27th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 30 studies in Carcinoma, Non-Small-Cell Lung by Incyte Corporation is open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Carcinoma, Non-Small-Cell Lung by Incyte Corporation, or all of them as a file.
02

Study summary

This is an open-label, single arm study to study the safety, efficacy and tolerability of Pemigatinib when used on participants with squamous or nonsquamous NSCLC with a documented FGFR1-3 mutations or fusions/rearrangement who have progressed on prior therapies and have no available standard treatment options

03

Conditions studied

  • Non-Small Cell Lung Cancer (NSCLC)

Keywords

  • Advanced Non-Small Cell Lung Cancer (NSCLC)
  • fibroblast growth factor receptor (FGFR)
  • FGFR1-3 mutations
  • FGFR1-3 fusions
  • FGFR1-3 rearrangements
  • squamous NSCLC
  • nonsquamous NSCLC
  • relapsed or refractory
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed advanced or NSCLC (Stage IIIB/C or IV per the AJCC Cancer Staging Manual, 8th Edition). Both squamous and nonsquamous NSCLC are eligible.
  • Radiographically (per v1.1). Tumor lesions located in a previously irradiated area, or in an area subjected to other loco-regional therapy, are considered measurable if progression has been clearly demonstrated in the lesion.
  • Documentation of known/likely actionable known or likely FGFR1-3 alterations.
  • Must have objective documented progression after at least 1 prior therapy, and must have no therapy available that is likely to provide clinical benefit. Participants who are intolerant of or decline the approved therapy are eligible only if they have no therapy available that is likely to provide clinical benefit.
  • performance status of 0 to 2.
  • Baseline (if less than 24 months from date of screening) or willingness to undergo a pretreatment tumor biopsy to obtain the specimen. Must be a tumor block or approximately 15 unstained slides from biopsy or resection of primary tumor or metastasis.
  • Willingness to avoid pregnancy or fathering a child.

Exclusion criteria

Exclusion Criteria

  • Prior receipt of a selective FGFR inhibitor.
  • Receipt of anticancer medications or drugs for any indication or reason within 28 days before the first dose of pemigatinib. Participants must have recovered (≤ Grade 1 as per v5.0 or at pretreatment baseline) from AEs from previously administered therapies (excluding alopecia).
  • Concurrent anticancer therapy (eg, chemotherapy, immunotherapy, biologic therapy, hormonal therapy, or investigational therapy).
  • Candidate for potentially curative surgery.
  • Current evidence of corneal (including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, and keratoconjunctivitis) or retinal disorder (including but not limited to macular/retinal degeneration, diabetic retinopathy, and retinal detachment) as confirmed by ophthalmologic examination.
  • Radiation therapy administered for the treatment of cancer lesions within 2 weeks before enrollment/first dose of study drug. Participants must have recovered from all radiation related toxicities, not require , and not have had radiation pneumonitis. Evidence of fibrosis within a radiation field from prior radiotherapy is permitted with medical monitor approval. A 1-week is permitted for palliative radiation to non-CNS disease.
  • Untreated brain or or brain or CNS metastases that have progressed (eg, evidence of new or enlarging brain metastasis or new neurological symptoms attributable to brain or CNS metastases). Participants who have previously treated and clinically stable brain or CNS metastases are eligible if there is no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period, and if they are on a stable or decreasing dose of corticosteroids for at least 1 week.
  • Known additional that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
  • Participants with defined laboratory values at screening.
  • History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues (exception: commonly observed calcifications in soft tissues such as the skin, kidney tendon, or vessels due to injury, disease, or aging in the absence of systemic mineral imbalance).
  • History of hypovitaminosis D requiring supraphysiologic doses (eg, 50,000 UI/weekly) to replenish the deficiency. Vitamin D supplements are allowed.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Cohort A: Squamous NSCLC

    Participants with squamous NSCLC with known or likely FGFR1-3 driver mutations outside the kinase domain or fusions/rearrangements will receive intermittent dosing.

    Drug: Pemigatinib

  • Experimental
    Cohort B: Non-squamous NSCLC

    Participants with non-squamous NSCLC with known or likely FGFR1-3 driver mutations outside the kinase domain or fusions/rearrangements will receive intermittent dosing.

    Drug: Pemigatinib

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) in Cohort A

    ORR was defined as the percentage of participants who achieved a complete response (CR) or a partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Response was determined by an Independent Central Radiology (ICR) review. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.

    Time frame: up to 267 days

Secondary outcomes

  1. ORR in Cohort B

    ORR was defined as the percentage of participants who achieved a CR or PR based on RECIST v1.1. Response was determined by an ICR review. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.

    Time frame: up to 80 days

  2. Progression-free Survival (PFS) in Cohort A

    PFS was defined as the time from the first dose of study treatment until progressive disease (PD) (according to RECIST v1.1 as assessed by an ICR review) or death, whichever occurred first. PD was defined as the progression of a target or non-target lesion or presence of a new lesion.

    Time frame: up to 267 days

  3. Duration of Response (DOR) in Cohort A

    DOR was defined as the time from the date of the first CR or PR until the date of the first PD (according to RECIST v1.1 as assessed by an ICR review) or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.

    Time frame: up to 182 days

  4. Overall Survival (OS) in Cohort A

    OS was defined as the time from the first dose of study treatment to death of any cause.

    Time frame: up to 267 days

  5. Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug-related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as an AE that was reported for the first time or the worsening of a pre-existing event after the first dose of pemigatinib and within 30 days of the last dose of pemigatinib.

    Time frame: up to 302 days

  6. Number of Participants With Any Treatment-related TEAE According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug-related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as an AE that was reported for the first time or the worsening of a pre-existing event after the first dose of pemigatinib and within 30 days of the last dose of pemigatinib. The investigator assessed the relationship between study drug and each occurrence of each AE/serious adverse event.

    Time frame: up to 302 days

07

Results

Posted Aug 6, 2024

Participant flow

Participant flow — Overall Study
MilestoneCohort A: Squamous NSCLCCohort B: Nonsquamous NSCLC
Started35
Completed00
Not completed35
Withdrew: Death14
Withdrew: Withdrawal by subject10
Withdrew: Study terminated by sponsor11

Outcome measures

PrimaryObjective Response Rate (ORR) in Cohort A

ORR was defined as the percentage of participants who achieved a complete response (CR) or a partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Response was determined by an Independent Central Radiology (ICR) review. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.

Time frame:
up to 267 days
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) in Cohort A
percentage of participantsCohort A: Squamous NSCLCCohort B: Nonsquamous NSCLC
Objective Response Rate (ORR) in Cohort A33.3 (0.84 to 90.57)—
SecondaryORR in Cohort B

ORR was defined as the percentage of participants who achieved a CR or PR based on RECIST v1.1. Response was determined by an ICR review. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.

Time frame:
up to 80 days
Reported as:
Number · percentage of participants
ORR in Cohort B
percentage of participantsCohort A: Squamous NSCLCCohort B: Nonsquamous NSCLC
ORR in Cohort B—0.0 (0.00 to 52.18)
SecondaryProgression-free Survival (PFS) in Cohort A

PFS was defined as the time from the first dose of study treatment until progressive disease (PD) (according to RECIST v1.1 as assessed by an ICR review) or death, whichever occurred first. PD was defined as the progression of a target or non-target lesion or presence of a new lesion.

Time frame:
up to 267 days
Reported as:
Median · months
Progression-free Survival (PFS) in Cohort A
monthsCohort A: Squamous NSCLCCohort B: Nonsquamous NSCLC
Progression-free Survival (PFS) in Cohort A8.31 (5.19 to NA)—
SecondaryDuration of Response (DOR) in Cohort A

DOR was defined as the time from the date of the first CR or PR until the date of the first PD (according to RECIST v1.1 as assessed by an ICR review) or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.

Time frame:
up to 182 days
Reported as:
Median · months
Duration of Response (DOR) in Cohort A
monthsCohort A: Squamous NSCLCCohort B: Nonsquamous NSCLC
Duration of Response (DOR) in Cohort ANA (NA to NA)—
SecondaryOverall Survival (OS) in Cohort A

OS was defined as the time from the first dose of study treatment to death of any cause.

Time frame:
up to 267 days
Reported as:
Median · months
Overall Survival (OS) in Cohort A
monthsCohort A: Squamous NSCLCCohort B: Nonsquamous NSCLC
Overall Survival (OS) in Cohort ANA (5.19 to NA)—
SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE)

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug-related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as an AE that was reported for the first time or the worsening of a pre-existing event after the first dose of pemigatinib and within 30 days of the last dose of pemigatinib.

Time frame:
up to 302 days
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsCohort A: Squamous NSCLCCohort B: Nonsquamous NSCLC
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)35
SecondaryNumber of Participants With Any Treatment-related TEAE According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug-related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as an AE that was reported for the first time or the worsening of a pre-existing event after the first dose of pemigatinib and within 30 days of the last dose of pemigatinib. The investigator assessed the relationship between study drug and each occurrence of each AE/serious adverse event.

Time frame:
up to 302 days
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-related TEAE According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0
ParticipantsCohort A: Squamous NSCLCCohort B: Nonsquamous NSCLC
Number of Participants With Any Treatment-related TEAE According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.035

Adverse events

Collected over up to 302 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: Squamous NSCLC1/3 (33.3%)0/3 (0%)3/3 (100%)
Cohort B: Nonsquamous NSCLC4/5 (80%)2/5 (40%)5/5 (100%)
Total5/8 (62.5%)2/8 (25%)8/8 (100%)
Most frequent serious events
Most frequent serious events
EventCohort A: Squamous NSCLCCohort B: Nonsquamous NSCLCTotal
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/31/51/8
HypotensionVascular disorders0/31/51/8
PneumoniaInfections and infestations0/31/51/8
Pulmonary sepsisInfections and infestations0/31/51/8
Respiratory tract infectionInfections and infestations0/31/51/8
Most frequent other events
Showing 10 of 75
Most frequent other events
EventCohort A: Squamous NSCLCCohort B: Nonsquamous NSCLCTotal
HyperphosphataemiaMetabolism and nutrition disorders3/33/56/8
ArthralgiaMusculoskeletal and connective tissue disorders2/30/52/8
DiarrhoeaGastrointestinal disorders2/33/55/8
Nail disorderSkin and subcutaneous tissue disorders2/30/52/8
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/30/52/8
RashSkin and subcutaneous tissue disorders2/31/53/8
StomatitisGastrointestinal disorders2/32/54/8
AstheniaGeneral disorders0/32/52/8
Blood creatinine increasedInvestigations1/32/53/8
Decreased appetiteMetabolism and nutrition disorders0/32/52/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort A: Squamous NSCLCCohort B: Nonsquamous NSCLCTotal
<=18 years000
Between 18 and 65 years156
>=65 years202
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: Squamous NSCLCCohort B: Nonsquamous NSCLCTotal
Female134
Male224
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A: Squamous NSCLCCohort B: Nonsquamous NSCLCTotal
Hispanic or Latino011
Not Hispanic or Latino336
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A: Squamous NSCLCCohort B: Nonsquamous NSCLCTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White347
More than one race000
Unknown or Not Reported011
08

Study locations

36 sites
  • Valkyrie Clinical Trials
    Los Angeles, California 90067, United States
  • Florida Cancer Specialists & Research Institute
    Fort Myers, Florida 33901, United States
  • Miami Cancer Institute
    Miami, Florida 33176, United States
  • Memorial Healthcare System
    Pembroke Pines, Florida 33028, United States
  • University of Kentucky Hospital
    Lexington, Kentucky 40536, United States
  • Spoknwrd Clinical Trials Inc.
    Easton, Pennsylvania 18045, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • H�PITAL NORD - CHU MARSEILLE
    Marseille, 13385, France
  • Chu de Toulouse Hopital Larrey Centre de Reference Des Maladies Rares de La Peau Service de Dermatol
    Toulouse, 31000, France
  • Zentralklinik Bad Berka Gmbh
    Bad Berka, 99437, Germany
  • Lungenklinik Hemer
    Hemer, 58675, Germany
  • Lki Lungenfachklinik Immenhausen
    Immenhausen, 34376, Germany
  • University Hospital Mannheim
    Mannheim, 68167, Germany
  • Irccs Centro Di Riferimento Oncologico
    Aviano, 33081, Italy
  • Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari
    Bari, 70124, Italy
  • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori
    Meldola, 47014, Italy
  • Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano
    Orbassano, 10043, Italy
  • Azienda Ospedaliera Di Perugia - Ospedale Santa Maria Della Misericordia
    Perugia, 06132, Italy
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, 56124, Italy
  • Istituto Nazionale Tumori Regina Elena Irccs
    Roma, 00144, Italy
  • Irccs Istituto Clinico Humanitas
    Rozzano, 20089, Italy
  • Complejo Hospitalario Universitario A Coruna
    A Coru?a, 15006, Spain
  • Hospital General Universitario Vall D Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital de La Santa Creu I Sant Pau
    Barcelona, 08041, Spain
  • Ico Girona Hospital Universitari de Girona Dr Josep Trueta
    Girona, 17007, Spain
  • Hospital Universitario Ciudad de Jaen
    Jaén, 23007, Spain
  • Ico Institut Catala D Oncologia
    L'Hospitalet de Llobregat, 08908, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Universitario Ramon Y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario de La Paz
    Madrid, 28046, Spain
  • Hospital Universitario Hm Sanchinarro
    Madrid, 28050, Spain
  • Hospital Regional Universitario de Malaga
    Málaga, 29010, Spain
  • Hospital Universitario Virgen Macarena
    Seville, 41009, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Aug 2023, 15 months.

Results were first posted in Aug 2024, 11 months after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 15 months is below that.

Counting every sponsor, half of 1,046 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2022
First posted
Feb 24, 2022
StartActual
Apr 29, 2022
Primary completionActual
Aug 16, 2023
CompletionActual
Aug 16, 2023
Results first posted
Aug 6, 2024
Last update
Aug 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05253807
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Feb 24, 2022
Start date
Apr 29, 2022
Primary completion
Aug 16, 2023
Completion
Aug 16, 2023
Results posted
Aug 6, 2024
Last update
Aug 5, 2025

Study contacts

Luisa Veronese, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemigatinib

Start the discussion